Company Encyclopedia
View More
name
Astellas Pharma
ALPMY.US
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
4.496 T
ALPMY.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking11/182
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.95%B
    • Profit Margin6.22%B
    • Gross Margin79.87%A
  • Growth ScoreB
    • Revenue YoY11.97%B
    • Net Profit YoY125.53%A
    • Total Assets YoY-4.66%D
    • Net Assets YoY0.84%C
  • Cash ScoreB
    • Cash Flow Margin1607.11%B
    • OCF YoY11.97%B
  • Operating ScoreB
    • Turnover0.58B
  • Debt ScoreC
    • Gearing Ratio53.27%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FDA Approves Pfizer and Astellas' PADCEV Plus Keytruda for Bladder Cancer

    The FDA has approved Pfizer and Astellas' PADCEV in combination with Keytruda for treating muscle-invasive bladder cancer in patients ineligible for cisplatin chemotherapy. This approval, based on the Phase 3 EV-303 trial, is the first perioperative treatment to show a survival advantage over surgery alone. The approval was granted earlier than expected.

    Reuters·
    US
    PFE
    +2.62%
    Reuters·
    US
    PFE
    +2.62%

    Astellas Pharma (OTCMKTS:ALPMY) Sets New 12-Month High - Time to Buy?

    Astellas Pharma (OTCMKTS:ALPMY) reached a new 52-week high at $12.72, closing at $12.14 with 92,947 shares traded. Analysts have downgraded the stock to 'Hold' from 'Outperform' and 'Strong-buy'. The company reported better-than-expected quarterly earnings, with $0.30 EPS and $3.45 billion revenue. Despite the high, analysts suggest other stocks may be better buys.

    Market Beat·
    US
    ALPMY
    +1.05%
    Market Beat·
    US
    ALPMY
    +1.05%

    Astellas Pharma's Attributable Profit Soars 101% in Fiscal H1

    Astellas Pharma's Attributable Profit Soars 101% in Fiscal H1

    marketscreener·
    US
    ALPMY
    +1.05%
    marketscreener·
    US
    ALPMY
    +1.05%

    Astellas Pharma Inc. Revises Consolidated Earnings Guidance for Fiscal Year 2025 Ending March 31, 2026

    Astellas Pharma Inc. revised consolidated earnings guidance for fiscal year 2025 ending March 31, 2026. For the year, the company now expects revenue of JPY 2,030,000 million against previous guidance of JPY 1,930,000 million, Operating profit of JPY 240,000 million against previous guidance of JPY 160,000 million, Profit for the year of JPY 180,000 million against previous guidance of JPY 130,000 million, and Basic earnings per share of JPY 100.50 per share against previous guidance of JPY 72.61.

    marketscreener·
    US
    ALPMY
    +1.05%
    marketscreener·
    US
    ALPMY
    +1.05%

    Pfizer Inc. (PFE) and Astellas Pharma Announce Survival Results from Phase 3 EMBARK Study

    Pfizer Inc. (NYSE:PFE) and Astellas Pharma US Inc. announced the final overall survival results from their Phase 3 EMBARK study on October 19. The study evaluated the effectiveness of XTANDI in combination with leuprolide as a monotherapy for men with non-metastatic hormone-sensitive prostate cancer. Pfizer is also noted as one of the most undervalued long-term stocks to buy right now.

    MSN·
    US
    ALPMY
    +1.05%
    US
    PFE
    +2.62%
    MSN·
    US
    ALPMY
    +1.05%
    US
    PFE
    +2.62%